<code id='6DFD11E314'></code><style id='6DFD11E314'></style>
    • <acronym id='6DFD11E314'></acronym>
      <center id='6DFD11E314'><center id='6DFD11E314'><tfoot id='6DFD11E314'></tfoot></center><abbr id='6DFD11E314'><dir id='6DFD11E314'><tfoot id='6DFD11E314'></tfoot><noframes id='6DFD11E314'>

    • <optgroup id='6DFD11E314'><strike id='6DFD11E314'><sup id='6DFD11E314'></sup></strike><code id='6DFD11E314'></code></optgroup>
        1. <b id='6DFD11E314'><label id='6DFD11E314'><select id='6DFD11E314'><dt id='6DFD11E314'><span id='6DFD11E314'></span></dt></select></label></b><u id='6DFD11E314'></u>
          <i id='6DFD11E314'><strike id='6DFD11E314'><tt id='6DFD11E314'><pre id='6DFD11E314'></pre></tt></strike></i>

          
          WSS
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment